Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Valensa Introduces New 'Body Ready' Astaxanthin Formulation for Optimal Absorption

Zanthin® XP-3 Astaxanthin delivers nature's most powerful antioxidant via a plant-based delivery system that decreases dose while increasing absorption in a safe, effective formula


News provided by

Valensa International

Mar 07, 2012, 08:15 ET

Share this article

Share toX

Share this article

Share toX

ANAHEIM, Calif., March 7, 2012 /PRNewswire/ -- Valensa International (Eustis, FL USA) announced today that it has launched a new Astaxanthin formulation that is designed to provide optimal absorption in support of human health at lower levels of ingestion. Called Zanthin® XP-3 Astaxanthin, the new product combines Valensa's Zanthin® Natural Astaxanthin with a supercritical extract Perilla seed oil, O2B™ Peroxidation Blocker stabilization system and sunflower-based phospholipids in a synergistic formulation that enhances the human body's absorption of the Astaxanthin. Published research has shown that absorption of Astaxanthin in the human body ranges from 25% to 90% in different individuals, and this can be greatly enhanced using natural plant-based oils and natural surfactant extracts. The published research also shows that large doses of Astaxanthin are disproportionally less absorbed compared to doses of 2 to 4 mg/day. Rather than adopt a strategy of large Astaxanthin doses to ensure the optimal 2 mg to 4 mg intake levels research has shown the body can utilize, Zanthin XP-3 typically makes the Astaxanthin 90% available across the board. As one of the fastest-growing nutritional supplements in the world today, studies have shown that Astaxanthin offers anti-aging support for the skin, for the brain and for eyes and joints. It has also been shown to support improved stamina, endurance and recovery from physical activity.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the critical factor for determining levels of Astaxanthin to use is that it is a fat-soluble substance. "With water-soluble substances such as Vitamin C, we need to take these every day in relatively high doses, because our body eliminates them rapidly. Fat-soluble substances, on the other hand, can linger in our bodies for up to 100 days. In the case of Astaxanthin, one dose has been shown to be detectable in serum for up to 72 hours and the known elimination half-life (T 1/2) - which is the time it takes for a substance to lose half of its original dose - is 16 hours. That means after a 24-hour period most people will still have slightly less than half of a previous dose still present as Astaxanthin in their blood serum and at the end of 24 hours, the next dosing cycle begins. The next dosing cycle results in even higher levels of serum Astaxanthin until a concentration called maximum serum concentration (CMax) is reached. Therefore, high daily doses of Astaxanthin are not needed because eventually even a tiny dose will reach CMax, where the concentration does not increase no matter what the dose. Zanthin XP-3 provides proper absorption, so that a 2 mg supplementation for general purposes or 4 mg Zanthin XP-3 for physical activity/endurance purposes is fully sufficient," he said.

"While there are clinical trials that show physiological benefits from 12 mg doses, the pharmacokinetics of astaxanthin indicate that these trials would have shown similar results at a 4 mg dose level. Scientists often use higher levels of a substance in studies to make sure that they can detect a measurable level in serum. In the case of Astaxanthin, depletion from serum is a competitive process with some getting used as fuel and the rest being deposited in membranes of your body, where it is primarily needed for its antioxidant function. What is not done so often is determining the lower levels that accomplish everything needed for efficacy. There are quite a number of trials at 2 mg and 4 mg levels that show positive health effects of Astaxanthin supplementation. I would fully expect that trials at 12 mg levels would give identical results as the 4 mg trials on our new super-absorbing Zanthin XP-3," he added.

He went on to point out that the Dietary Reference Intake (DRI) from the Institute of Medicine (IOM) for Beta-carotene - a researched similar substance - is 1.8 mg. While not a perfect surrogate, since it does not have the same polarity or absorption, it is less active in vitro than astaxanthin.

The most "body ready" Astaxanthin available today

Astaxanthin, like other carotenoids, is a very fat-soluble compound with moderate to good oral bioavailability. It is best consumed with fatty foods including eggs, whole milk or alpha linolenic acid (ALA)-containing nuts, such as walnuts. Studies have shown that absorption of Astaxanthin is enhanced in the presence of fats, surfactants or phospholipids (Odeberg, MJ, A. Lignell, A. Pettersson and P. Hoglund, 2003). The delivery package for Astaxanthin used in Zanthin XP-3 combines phospholipids from sunflowers and lipophilic Perilla oil. The Perilla seed extract in Zanthin XP-3 is made from select seeds of the Perilla frutescens plant and extracted using Valensa's proprietary Deep Extract(R) extraction process. This Perilla seed extract oil has the highest ratio of Omega-3 to Omega-6 fatty acids of any known seed oil, an astonishing 6:1. ALA Omega-3 fatty acids are known to aid in the absorption of Astaxanthin and as such, greatly improve its bioavailability. Zanthin XP-3 is available in bulk, softgels and in two-piece, vegetarian liquid capsules.

According to Dr. Moerck, while Astaxanthin is widely regarded as a safe ingredient, retailers and suppliers should focus on developing products that meet people's needs in the most efficient manner. "As a supplier of Astaxanthin, you might ask why Valensa is recommending lower dosage levels. The answer is pretty straightforward - because for Astaxanthin, more isn't better and we want to develop and recommend the best, most cost-effective products to our customers," he said. "To consumers I'd say: Try the lower levels of supplementation first, and see how you feel. Trust your body," he added.

For further information, contact:

Dr. Rudi Moerck, President & CEO
Voice: 210-632-0695
Fax: 352-483-2095
http://www.valensa.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Valensa International

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.